AIP
NGNE icon

Ameritas Investment Partners’s Neurogene NGNE Stock Holding History

Ameritas Investment Partners’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.3K Hold
1,009
– – ﹤0.01% 2589
2025
Q4 		$20.8K Hold
1,009
– – ﹤0.01% 2618
2025
Q3 		$17.5K Hold
1,009
– – ﹤0.01% 2726
2025
Q2 		$15.1K Hold
1,009
– – ﹤0.01% 2791
2025
Q1 		$11.8K Hold
1,009
– – ﹤0.01% 2768
2024
Q4 		$23.1K Hold
1,009
– – ﹤0.01% 2566
2024
Q3 		$42.3K Hold
1,009
– – ﹤0.01% 2290
2024
Q2 		$36.7K Buy
+1,009
New +$35.6K ﹤0.01% 2308
2022
Q2 		– Sell
-131
Closed -$5K – 3178
2022
Q1 		$5K Hold
131
– – ﹤0.01% 2972
2021
Q4 		$13K Hold
131
– – ﹤0.01% 2821
2021
Q3 		$19K Hold
131
– – ﹤0.01% 2733
2021
Q2 		$24K Hold
131
– – ﹤0.01% 2650
2021
Q1 		$32K Hold
131
– – ﹤0.01% 2339
2020
Q4 		$37K Hold
131
– – ﹤0.01% 2158
2020
Q3 		$31K Hold
131
– – ﹤0.01% 2144
2020
Q2 		$44K Buy
+131
New +$34.1K ﹤0.01% 1912

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Ameritas Investment Partners's NGNE Position: Q1 2026 in Review

Ameritas Investment Partners held its Neurogene (NGNE) position steady in Q1 2026 at 1,009 shares worth $20.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2589.

Ameritas Investment Partners first reported a position in NGNE in Q2 2020 and has held it in 16 quarters since. The position peaked at $44K in Q2 2020. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Ameritas Investment Partners held 1,009 shares of Neurogene worth $20.3K as of Q1 2026.
  • Ameritas Investment Partners left its Neurogene share count unchanged in Q1 2026.
  • Neurogene made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2589 holding.
  • Ameritas Investment Partners first reported a position in Neurogene in Q2 2020 and has held it in 16 quarters since.
  • Ameritas Investment Partners's Neurogene position peaked at $44K in Q2 2020.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.